‘Hepatitis C market forecast for 230% growth in next nine years’.
Growth to be driven by fierce competition in new drug development
Research from Datamonitor Healthcare, the leading independent healthcare analyst, has revealed that the Hepatitis C market is forecast to grow by 230 per cent, peaking at $15.5bn in 2022. Gilead’s highly anticipated drug sofosbuvir will be the main contributor to market value as it has demonstrated promising results in clinical trials.
Fierce competition between several big pharma companies including AbbVie, Johnson & Johnson and Bristol-Myers Squibb, will also drive this market growth as they rush to develop improved interferon-free regimens.
Sabada Dube, lead epidemiologist at Datamonitor Healthcare, said: “Despite recent clinical breakthroughs, Hepatitis C remains a huge public health problem across the world with 7 million people currently living with the virus across the US, Japan and 5 major EU markets*. The number of people living with hepatitis C in these markets is forecast to increase except in Japan where marginal declines in infected people is expected.”
Michael Haydock, analyst at Datamonitor Healthcare, said: “Traditional interferon-based therapies suffer from poor tolerability profiles and lengthy treatment durations, and the prevalence of infections is predicted to increase by 200,000 by the year 2022. Therefore, the demand for new and improved interferon-free drugs is only going to rise.
“In short, we’re expecting the market value to soar.”
*The 5 major EU markets are France, Germany, Italy, Spain and the UK.
About Datamonitor Healthcare…
Datamonitor Healthcare is the leading independent source of expert research across key pharmaceutical and biotechnology sectors. Our event-sensitive analysis evolves alongside the market to provide the most timely and representative market insight, supported by robust sources and methodologies that validate forecasts and assumptions. Rely on our global team of expert analysts, journalists and thought leaders to help you monitor and respond to spontaneous and disruptive industry developments.
For more information on this research, please Contact Us